Fig. 2From: First-in-human study of GFH018, a small molecule inhibitor of transforming growth factor-β receptor I inhibitor, in patients with advanced solid tumorsMean (+SD) plasma concentration-time profiles of GFH018 (left panel: single dose; right panel: multiple dose). Cohort 85mg A represents 85 mg BID 7d-on/7d-off regimen. Cohort 85mg B represents 85 mg BID 14d-on/14d-off regimenBack to article page